Ideaya Biosciences

Yahoo Finance • 3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on Septem... Full story

Yahoo Finance • 8 months ago

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Bioscience... Full story

Yahoo Finance • 10 months ago

IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares

On February 9, 2024, Yujiro Hata, the President and CEO of IDEAYA Biosciences Inc (NASDAQ:IDYA), sold 99,372 shares of the company. The transaction was reported in a SEC Filing. Following this transaction, the insider's total sales over th... Full story

Yahoo Finance • last year

IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million estimated net proceeds from subsequent follow-on financing and $10.0 million receivable fro... Full story

Yahoo Finance • 2 years ago

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 223% over the past three years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the IDEAYA Bioscie... Full story

Yahoo Finance • 2 years ago

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, annou... Full story

Yahoo Finance • 2 years ago

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

- Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer - Starting dose of IDE161 in the Phase 1 dose escalation is one-... Full story

Yahoo Finance • 2 years ago

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

­First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane in MTAP-deletion tumors Clinical strate... Full story

Yahoo Finance • 2 years ago

‘The Market Bottom Is Near,’ Says Oppenheimer — Here Are 2 Stocks to Play That Bullish Sentiment

In a market trending down, there are fewer scenarios more appealing to investors than ones outlining bearish sentiment is about to turn positive. And according to Ari Wald, head of technical analysis at Oppenheimer, we’re on the cusp of on... Full story

Yahoo Finance • 2 years ago

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate

Preclinical development milestone achieved in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC as combo with niraparib Potential to realize preclinical and clinical milestones up to $20... Full story